Carlet J, Collignon P, Goldmann D, Goossens H, Gyssens IC, Harbarth S, Jarlier V, Levy SB, N'doye B, Pittet D, Richtmann R, Seto WH, Van der Meer JW, Voss A: Society's failure to protect a precious resource: antibiotics. Lancet 2011,378(9788):369–371. 10.1016/S0140-6736(11)60401-7
Article
PubMed
Google Scholar
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009,48(1):1–12. 10.1086/595011
Article
PubMed
Google Scholar
Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibiotic dosing of mice and men. Clin Infect Dis 1998, 26: 1–10. 10.1086/516284
Article
CAS
PubMed
Google Scholar
Mouton JW, Vinks AA: Is continuous infusion of beta-lactam antibiotics worthwhile?–efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996,38(1):5–15. 10.1093/jac/38.1.5
Article
CAS
PubMed
Google Scholar
Mouton JW, Punt N, Vinks AA: Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo. Antimicrob Agents Chemother 2007,51(9):3449–3451. 10.1128/AAC.01586-06
Article
CAS
PubMed Central
PubMed
Google Scholar
Craig WA: Interrelationship between pharmacokinetics and pharmacodynamics in determining dosing regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995, 22: 89–96. 10.1016/0732-8893(95)00053-D
Article
CAS
PubMed
Google Scholar
Craig WA: Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis 1996, 25: 213–217. 10.1016/S0732-8893(96)00162-9
Article
CAS
PubMed
Google Scholar
McKinnon PS, Paladino JA, Schentag JJ: Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008,31(4):345–351. 10.1016/j.ijantimicag.2007.12.009
Article
CAS
PubMed
Google Scholar
Mouton JW, den Hollander JG: Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994,38(5):931–936. 10.1128/AAC.38.5.931
Article
CAS
PubMed Central
PubMed
Google Scholar
Alou L, Aguilar L, Sevillano D, Giménez MJ, Echeverría O, Gómez-Lus ML, Prieto J: Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa: An in vitro pharmacodynamic model. J Antimicrob Chemother 2005,55(2):209–213. 10.1093/jac/dkh536
Article
CAS
PubMed
Google Scholar
Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ: Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 1999,43(2):309–311. 10.1093/jac/43.2.309
Article
CAS
PubMed
Google Scholar
Jaruratanasirikul S, Sriwiriyajan S, Punyo J: Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005,49(4):1337–1339. 10.1128/AAC.49.4.1337-1339.2005
Article
CAS
PubMed Central
PubMed
Google Scholar
De Jongh R, Hens R, Basma V, Mouton JW, Tulkens PM, Carryn S: Continuous versus II of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008,61(2):382–388.
Article
CAS
PubMed
Google Scholar
Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sörgel F: Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007,51(7):2497–2507. 10.1128/AAC.01477-06
Article
CAS
PubMed Central
PubMed
Google Scholar
Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J: Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009,64(1):142–150. 10.1093/jac/dkp139
Article
CAS
PubMed
Google Scholar
Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, Fazeli MR: Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006,28(2):122–127. 10.1016/j.ijantimicag.2006.02.020
Article
CAS
PubMed
Google Scholar
Van Zanten AR, Oudijk M, Nohlmans-Paulssen MK, van der Meer YG, Girbes AR, Polderman KH: Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharmacol 2007,63(1):100–109. 10.1111/j.1365-2125.2006.02730.x
Article
CAS
PubMed Central
PubMed
Google Scholar
Mariat C, Venet C, Jehl F, Mwewa S, Lazarevic V, Diconne E, Fonsale N, Carricajo A, Guyomarc'h S, Vermesch R, Aubert G, Bidault R, Bertrand JC, Zeni F: Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous hemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit Care 2006,10(1):R26. 10.1186/cc3993
Article
PubMed Central
PubMed
Google Scholar
Udy AA, Putt MT, Shanmugathasan S, Roberts JA, Lipman J: Augmented renal clearance in the Intensive Care Unit: an illustrative case series. Int J Antimicrob Agents 2010,35(6):606–608. 10.1016/j.ijantimicag.2010.02.013
Article
CAS
PubMed
Google Scholar
Roberts JA, Lipman J: Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006,45(8):755–773. 10.2165/00003088-200645080-00001
Article
CAS
PubMed
Google Scholar
Roosendaal R, Bakker-Woudenberg IA, Van den Berghe-Van Raffe M, den Berg JC V-V, Michel BM: Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis 1989, 8: 878–887. 10.1007/BF01963774
Article
CAS
PubMed
Google Scholar
Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Michel MF: Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 1986, 30: 403–408. 10.1128/AAC.30.3.403
Article
CAS
PubMed Central
PubMed
Google Scholar
Roosendaal R, Bakker-Woudenberg IA, van den Berg JC, Michel MF: Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J Infect Dis 1985, 152: 373–378. 10.1093/infdis/152.2.373
Article
CAS
PubMed
Google Scholar
Roosendaal R, Bakker-Woudenberg IA: Impact of the antibiotic dosage schedule on efficacy in experimental lung infections. Scand J Infect Dis 1990, 74: 155–162.
CAS
Google Scholar
Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V, Chaowagul W, White NJ: Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 2000, 50: 184–191. 10.1111/j.1365-2125.2000.00179.x
Article
CAS
PubMed Central
PubMed
Google Scholar
Buijk SL, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA, Bruining HA: Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 2002,49(1):121–128. 10.1093/jac/49.1.121
Article
CAS
PubMed
Google Scholar
Benko AS, Cappelletty DM, Kruse JA, Rybak MJ: Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996, 40: 691–695.
CAS
PubMed Central
PubMed
Google Scholar
Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, Boucher BA: Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000,179(6):436–440. 10.1016/S0002-9610(00)00388-3
Article
CAS
PubMed
Google Scholar
Boselli E, Breilh D, Rimmele T, et al.: Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004, 30: 989–991. 10.1007/s00134-004-2171-2
Article
PubMed
Google Scholar
Jaruratanasirikul S, Sriwiriyajan S, Ingviya N: Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia. J Pharm Pharmacol 2002, 54: 1693–1696.
Article
CAS
PubMed
Google Scholar
Boselli E, Breilh D, Duflo F, et al.: Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 2003, 31: 2102–2106. 10.1097/01.CCM.0000069734.38738.C8
Article
CAS
PubMed
Google Scholar
Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP: Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005,56(2):388–395. 10.1093/jac/dki243
Article
CAS
PubMed
Google Scholar
Roberts JA, Roberts MS, Dalley A, Cross SE, Lipman J: Exposure and predicted antimicrobial efficacy in critically ill patients: piperacillin. In The Society of Hospital Pharmacists of Australia: Queensland Branch Conference; 21–22 October 2006. Australia: SHPA, Brisbane; 2006.
Google Scholar
Roberts JA, Webb S, Paterson D, Ho KM, Lipman J: A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009,37(6):2071–2078. 10.1097/CCM.0b013e3181a0054d
Article
CAS
PubMed
Google Scholar
Roberts JA, Boots R, Rickard CM, Thomas P, Quinn J, Roberts DM, Richards B, Lipman J: Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007,59(2):285–291.
Article
CAS
PubMed
Google Scholar
Bodey GP, Ketchel SJ, Rodriguez V: A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979,67(4):608–616. 10.1016/0002-9343(79)90242-0
Article
CAS
PubMed
Google Scholar
Lagast H, Meunier-Carpentier F, Klastersky J: Treatment of gram-negative bacillary septicemia with cefoperazone. Eur J Clin Microbiol 1983,2(6):554–558. 10.1007/BF02016564
Article
CAS
PubMed
Google Scholar
Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH: Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001,17(6):497–504. 10.1016/S0924-8579(01)00329-6
Article
CAS
PubMed
Google Scholar
Pedeboscq S, Dubau B, Frappier S, Hernandez V, Veyssières D, Winnock S, Pometan JP: Comparison of 2 administration protocols (continuous or discontinuous) of a time-dependent antibiotic, Tazocin. Pathol Biol 2001, 49: 540–547. 10.1016/S0369-8114(01)00210-3
Article
CAS
PubMed
Google Scholar
Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD: Pharmacokinetics of piperacillin-tazobactam: Intermittent dosing versus continuous infusion. Int J Antimicrob Agents 2005, 25: 62–67. 10.1016/j.ijantimicag.2004.08.012
Article
CAS
PubMed
Google Scholar
Georges B, Conil JM, Cougot P, Decun JF, Archambaud M, Seguin T, Chabanon G, Virenque C, Houin G, Saivin S: Cefepime in critically ill patients: Continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther 2005, 43: 360–369.
Article
CAS
PubMed
Google Scholar
Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, Dana A: Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006, 50: 3556–3561. 10.1128/AAC.00329-06
Article
CAS
PubMed Central
PubMed
Google Scholar
Kojika M, Sato N, Hakozaki M, Suzuki Y, Takahasi G, Endo S, Suzuki K, Wakabayasi G: A preliminary study of the administration of carbapenem antibiotics in sepsis patients on the basis of the administration time. Jpn J Antibiot 2005,58(5):452–457.
PubMed
Google Scholar
Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sörgel F: Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007, 51: 3304–3310. 10.1128/AAC.01318-06
Article
CAS
PubMed Central
PubMed
Google Scholar
Walton AL, Howden BP, Grayson LM, Korman TM: Continuous-infusion penicillin home-based therapy for serious infections due to penicillin-susceptible pathogens. Int J Antimicrob Agents 2007,29(5):544–548. 10.1016/j.ijantimicag.2006.10.018
Article
CAS
PubMed
Google Scholar
Howden BP, Richards MJ: The efficacy of continuous infusion flucloxacillin in home therapy for serious staphylococcal infections and cellulitis. J Antimicrob Chemother 2001,48(2):311–314. 10.1093/jac/48.2.311
Article
CAS
PubMed
Google Scholar
Leder K, Turnidge JD, Korman TM, Grayson ML: The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. J Antimicrob Chemother 1999,43(1):113–118. 10.1093/jac/43.1.113
Article
CAS
PubMed
Google Scholar
Hughes DW, Frei CR, Maxwell PR, Green K, Patterson JE, Crawford GE, Lewis JS: Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2009,53(5):2014–2019. 10.1128/AAC.01232-08
Article
CAS
PubMed Central
PubMed
Google Scholar
Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R: Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002,22(4):471–483. 10.1592/phco.22.7.471.33665
Article
CAS
PubMed
Google Scholar
Lodise TP, Lomaestro B, Drusano GL: Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007,44(3):357–363. 10.1086/510590
Article
CAS
PubMed
Google Scholar
Lorente L, Jiménez A, Martín MM, Iribarren JL, Jiménez JJ, Mora ML: Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009,33(5):464–468. 10.1016/j.ijantimicag.2008.10.025
Article
CAS
PubMed
Google Scholar
Lorente L, Jiménez A, Palmero S, Jiménez JJ, Iribarren JL, Santana M, Martín MM, Mora ML: Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther 2007,29(11):2433–2439. 10.1016/j.clinthera.2007.11.003
Article
CAS
PubMed
Google Scholar
Lorente L, Lorenzo L, Martín MM, Jiménez A, Mora ML: Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006,40(2):219–223. 10.1345/aph.1G467
Article
CAS
PubMed
Google Scholar
Daikos GL, Markogiannakis A: Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011,17(8):1135–1141. 10.1111/j.1469-0691.2011.03553.x
Article
CAS
PubMed
Google Scholar
McNabb JJ, Nightingale CH, Quintiliani R, Nicolau DP: Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 2001,21(5):549–555. 10.1592/phco.21.6.549.34539
Article
CAS
PubMed
Google Scholar
Mouton JW, Vinks AA: Continuous infusion of beta-lactams. Curr Opin Crit Care 2007,13(5):598–606. 10.1097/MCC.0b013e3282e2a98f
Article
PubMed
Google Scholar
Martin JH, Fay MF, Udy A, Roberts J, Kirkpatrick C, Ungerer J, Lipman J: Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Intern Med J 2011,41(7):537–543. 10.1111/j.1445-5994.2009.02160.x
Article
CAS
PubMed
Google Scholar
Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F: Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010,14(4):R126. 10.1186/cc9091
Article
PubMed Central
PubMed
Google Scholar
Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM: Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002,46(8):2327–2332. 10.1128/AAC.46.8.2327-2332.2002
Article
CAS
PubMed Central
PubMed
Google Scholar
Vinks AA, Touw DJ, van Rossen RC, Heijerman HG, Bakker W: Stability of aztreonam in a portable pump reservoir used for home intravenous antibiotic treatment (HIVAT). Pharm World Sci 1996,18(2):74–77. 10.1007/BF00579709
Article
CAS
PubMed
Google Scholar
Servais H, Tulkens PM: Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001,45(9):2643–2647. 10.1128/AAC.45.9.2643-2647.2001
Article
CAS
PubMed Central
PubMed
Google Scholar
Baririan N, Chanteux H, Viaene E, Servais H, Tulkens PM: Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003,51(3):651–658. 10.1093/jac/dkg134
Article
CAS
PubMed
Google Scholar
Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulkens PM: Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 2010,65(5):1073–1075. 10.1093/jac/dkq044
Article
CAS
PubMed
Google Scholar
Trissel : Handbook on infectible drugs. 15th edition. Bethesda: America Society of Health System Pharmacists; 2009.
Google Scholar
Vella-Brincat JW, Begg EJ, Gallagher K, Kirkpatrick CM, Zhang M, Frampton C, Chambers ST: Stability of benzylpenicillin during continuous home intravenous therapy. J Antimicrob Chemother 2004,53(4):675–677. 10.1093/jac/dkh146
Article
CAS
PubMed
Google Scholar
Craig WA: Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003,17(3):479–501. 10.1016/S0891-5520(03)00065-5
Article
PubMed
Google Scholar
Ebert S: vivo cidal activity and pharmacokinetic parameters for vancomycin against methicillin-susceptible and -resistant S. aureus [abstract 439]. In Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy (New York). Washington, DC: American Society for Microbiology; 1987:173.
Google Scholar
Dudley M, Griffith D, Corcoran E, Liu C, Sorensen K, Tembe V: PK/PD indices for vancomycin treatment of susceptible (VSSA) and intermediate (VISA) S. aureus in the neutropenic murine thigh model. In Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington: American Society for Microbiology; 1999:49.
Google Scholar
Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ: Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004,43(13):925–942. 10.2165/00003088-200443130-00005
Article
CAS
PubMed
Google Scholar
Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, Dalovisio JR, Levine DP: Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009,66(1):82–98. 10.2146/ajhp080434
Article
CAS
PubMed
Google Scholar
Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, Timsit JF, Similowski T, Mentec H, Mier L, Dreyfuss D: Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001,45(9):2460–2467. 10.1128/AAC.45.9.2460-2467.2001
Article
CAS
PubMed Central
PubMed
Google Scholar
Vuagnat A, Stern R, Lotthe A, Schuhmacher H, Duong M, Hoffmeyer P, Bernard L: High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther 2004,29(4):351–357. 10.1111/j.1365-2710.2004.00572.x
Article
CAS
PubMed
Google Scholar
Di Filippo A, De Gaudio AR, Novelli A, Paternostro E, Pelagatti C, Livi P, Novelli GP: Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection. Chemotherapy 1998,44(1):63–68. 10.1159/000007092
Article
CAS
PubMed
Google Scholar
Rello J, Sole-Violan J, Sa-Borges M, Garnacho-Montero J, Muñoz E, Sirgo G, Olona M, Diaz E: Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005,33(9):1983–1987. 10.1097/01.CCM.0000178180.61305.1D
Article
CAS
PubMed
Google Scholar
Ingram PR, Lye DC, Fisher DA, Goh WP, Tam VH: Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents 2009,34(6):570–574. 10.1016/j.ijantimicag.2009.07.011
Article
CAS
PubMed
Google Scholar
Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Müller M, Tschernko E: Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion. Anesthesiology 2009,111(2):356–365. 10.1097/ALN.0b013e3181a97272
Article
CAS
PubMed
Google Scholar
Byl B, Jacobs F, Wallemacq P, Rossi C, de Francquen P, Cappello M, Leal T, Thys JP: Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion. Antimicrob Agents Chemother 2003,47(6):2015–2017. 10.1128/AAC.47.6.2015-2017.2003
Article
CAS
PubMed Central
PubMed
Google Scholar
Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N: Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012,67(1):17–24. 10.1093/jac/dkr442
Article
CAS
PubMed
Google Scholar
Spapen HD, Janssen van Doorn K, Diltoer M, Verbrugghe W, Jacobs R, Dobbeleir N, Honoré PM, Jorens PG: Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. Ann Intensive Care 2011,19(1):1–26.
Google Scholar
Gupta A, Biyani M, Khaira A: Vancomycin nephrotoxicity: myths and facts. Neth J Med 2011,69(9):379–383.
CAS
PubMed
Google Scholar
Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak JM, Talan DA, Chambers HF: Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011,52(3):18–55. 10.1093/cid/ciq146
Article
Google Scholar
Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA: Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008,62(1):168–171. 10.1093/jac/dkn080
Article
CAS
PubMed
Google Scholar
Jeurissen A, Sluyts I, Rutsaert R: A higher dose of vancomycin in continuous infusion is needed in critically ill patients. Int J Antimicrob Agents 2011,37(1):75–77. 10.1016/j.ijantimicag.2010.09.004
Article
CAS
PubMed
Google Scholar